Journal of Clinical Oncology
Articles in this Issue
Personalized ctDNA monitoring to assess the recurrence of early stage pancreatic cancer after surgery.
774 Background: Up to 80% of patients with resected pancreatic cancer recur within 2 years. Here, we assessed the feasibility and accuracy of a personaliz...
Racial disparities in secondary metastasis in patients with hepatocellular carcinoma: A 5-year National Inpatient Sample study.
523 Background: Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the leading causes of cancer-related mortality worldwide. The incide...
EQUITY GI: A prospective study to enhance quality, inclusivity, and trial participation in Black patients with gastrointestinal cancer.
TPS843 Background: Black individuals, including African Americans, experience a disproportionate cancer burden and exhibit the lowest survival rates among...
Utilization of circulating tumor DNA (ctDNA) testing in biliary tract cancers.
644 Background: There is limited data to guide surveillance in biliary tract cancers (BTCs) following resection. Minimal residual disease (MRD) assays uti...
Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study.
454 Background: ASKB589 is a non-fucosylated fully human IgG1 monoclonal antibody that binds CLDN18.2 with high affinity, specificity, and improved ADCC a...
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
426 Background: Regulatory T-cells (T regs ) suppress anti-tumor immunity by migrating into tumors via CCL17/CCL22 chemokines bind...
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
206 Background: XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding aCTLA-4 designed to block CTLA-4 and deplete regulatory T...
A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).
TPS314 Background: Epidermal growth factor receptor (EGFR) inhibitorcombined withchemotherapy based on5-FU with oxaliplatin and irinotecanis the first-lin...
Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI).
272 Background: Microsatellite instability (MSI) is linked to hypermutability and response to ICI(s), especially in colorectal cancer. The predictive impa...
Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.
727 Background: PARP inhibition (PARPi) is a standard maintenance therapy for patients (pts) with germline BRCA1/2 mutations in pa...
Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: The α-CORRECT study.
302 Background: Patients with stage III CRC undergo surgery and adjuvant chemotherapy. Evaluation of MRD using a highly sensitive and specific, tumor-info...
A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
407 Background: Preliminary results of the open-label, single-arm phase II study (NCT05625737) had demonstrated the combination of fruquintinib and sintil...
Clinical outcomes of immunotherapy in metastatic pancreatic carcinoma: A systematic review and meta-analysis.
688 Background: Metastatic pancreatic carcinoma is one of the most challenging malignancies to treat. Traditional treatment modalities such as chemotherap...
Optimizing clinical trial design to mitigate racial disparities in pancreatic cancer clinical trial enrollment.
682 Background: Participation in pancreatic ductal adenocarcinoma (PDAC) clinical trials remains dismal among patients from minoritized groups. This study...
Assessment of nutritional status in elderly patients with gastroesophageal cancer: A post hoc analysis.
389 Background: Elderly patients with gastroesophageal cancer (GEC) frequently suffer from malnutrition due to tumor location and treatment-related toxici...
Radiomics-based prediction of HCC response to atezolizumab/bevacizumab.
636 Background: Advanced hepatocellular carcinoma (HCC) treatment has evolved with the introduction of atezolizumab/bevacizumab, showing improved outcomes...
Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAF <sup>V600E</sup> -mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.
TPS316 Background: Current first-line treatment regimen for advanced colorectal cancer with BRAF V600E gene mutation is chemothera...
The prevalence and prognostic significance of <i>KRAS G12C</i> mutation in metastatic colorectal cancer.
289 Background: Kristen rat sarcoma virus ( KRAS ) mutations are reported in 40-45% of colorectal cancer (CRC), and they are assoc...
Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.
360 Background: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody an...
The effect of renin-angiotensin system inhibitors on patients with pancreatic cancer receiving systemic treatment: A retrospective cohort study from TriNetX US collaborative networks.
734 Background: This study aimed to assess the impact of renin-angiotensin system inhibitors, including angiotensin receptor blockers (ARBs) and angiotens...
More isn't always better: Expanding and refining prognostic methylation signatures for pancreatic ductal adenocarcinoma.
769 Background: In our previous study, we developed protein-informed methylation signatures from a chemoresistance gene panel (RGp, n=122) curated from th...
Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE).
LBA522 Background: Transarterial chemoembolization (TACE) has been established as a standard treatment for hepatocellular carcinoma (HCC) eligible for emb...
Survival benefits of adjuvant chemotherapy after surgical resection of para-aortic lymph node metastasis from colorectal cancer: A multicenter retrospective study.
140 Background: Surgical removal of metastasized paraaortic lymph nodes (PALNs) can prolong the survival of certain patients with colorectal cancer (CRC)....
Correlation of tumoral collagen width with overall survival and tumoral collagen straightness with distant recurrence-free survival in patients with pancreatic ductal adenocarcinoma.
779 Background: Quantitative measurements of fibrillar collagen characteristics has been shown to correlate with survival in several types of malignancy....
The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression.
159 Background: The PARADIGM study in CRC patients demonstrated a cross over of the bevacizumab survival curve below the panitumumab survival curve at 28...